Headache determines quality of life in idiopathic intracranial hypertension

Yasmeen Mulla1, Keira A Markey1, Rebecca L Woolley2, Smitaa Patel2, Susan P Mollan3 and Alexandra J Sinclair1*

Abstract

Background: The effect of idiopathic intracranial hypertension (IIH) on quality of life (QOL) is poorly understood. Our objectives were to compare QOL in IIH to the normal UK population; to investigate QOL changes with treatment of IIH, using a weight loss intervention, and to determine which clinical factors influence QOL.

Methods: This was a prospective cohort evaluation of QOL, using the 36-Item Short Form (SF-36) Health Survey questionnaire, before and after a therapeutic dietary intervention which resulted in significant reduction in body mass index (BMI), intracranial pressure (ICP), papilloedema, visual acuity, perimetric mean deviation (Humphrey 24–2) and headache (six-item headache impact test (HIT-6) and headache diary). Baseline QOL was compared to an age and gender matched population. The relationship between each clinical outcome and change in QOL was evaluated.

Results: At baseline, QOL was significantly lower in IIH compared to an age and gender matched population in most domains, p < 0.001. Therapeutic weight loss led to a significant improvement in 10 out of 11 QOL domains in conjunction with the previously published data demonstrating significant improvement in papilloedema, visual acuity, perimetry and headache (p < 0.001) and large effect size. Despite significant improvement in clinical measures only headache correlated significantly (p < 0.001) with improving QOL domains.

Conclusions: QOL in IIH patients is significantly reduced. It improved with weight loss alongside significant improvement in clinical measures and headache. However, headache was the only clinical outcome that correlated with enhanced QOL. Effective headache management is required to improve QOL in IIH.

Keywords: Idiopathic intracranial hypertension; Headache; Quality of life; SF-36

Background

Idiopathic intracranial hypertension (IIH), also known as primary pseudotumour cerebri and previously benign intracranial hypertension, is characterised by increased intracranial pressure (ICP) and papilloedema in the setting of brain imaging with no evidence of space occupying lesion or venous thrombosis [1,2]. The condition commonly affects young, obese women (incidence in obese female population 11-21/100,000/year) and causes headaches and visual loss [3-5]. To date clinical and research outcomes have focussed on vision and to a lesser extent headache. The previously reported rates of visual loss (25% permanent severe blindness) are likely to be an overestimate, particularly in specialist centres: yet many IIH patients remain very disabled by the condition [6,7].

There is a paucity of the literature evaluating QOL in IIH with currently only three previous published studies [8-10]. QOL in IIH is not different compared to an age, gender and BMI matched population in the domains of vitality, mental health and role limitation due to emotional problems, implying there are factors besides obesity in determining QOL in IIH [8]. QOL has been shown to improve following treatment with acetazolamide, however it was unclear which factors contributed to the improvement in QOL [10]. QOL in IIH has also been shown to be impaired compared to other neuro-ophthalmic disorders [9].

Our objective was to characterise QOL in an adult IIH cohort in the United Kingdom and compare it to an age
and gender matched normal population. We then sought
to assess QOL in the cohort following a therapeutic diet-
ary intervention. QOL parameters were compared to clin-
cical outcome measures to evaluate which factors were
associated with positive changes in QOL.

Methods
Evaluations were conducted alongside a previously re-
ported prospective multicentre cohort study which doc-
uments the full protocol [11]. In summary, twenty five
females with IIH, over the age of 16 years, consented to
participate in the study. IIH was diagnosed in accord-
ance with the updated modified Dandy Criteria [2]. All
participants had a disease duration of 3 months and
signs of active disease with raised ICP pressure >25
cmCSF and papilloedema. Magnetic resonance imaging
and venography did not reveal alternative pathology in
all those recruited.

Study design
The study was a prospective cohort evaluation consisting
of two stages each lasting 3 months with a follow up visit
at 9 months: Stage 1 (0–3 months): no intervention and
Stage 2 (3–6 months): low calorie diet. The intervention
period involved each woman receiving a nutritionally
complete low calorie liquid replacement diet (Lipotrim,
Howard Foundation, Cambridge) of 425 kcal/day.

Subjects were evaluated at baseline, 3 months, 6 months
and a follow up visit at 9 months. The primary outcome
measure was quality of life, using the validated 36-Item
Short Form Health Survey questionnaire (version 1)
[12-14]. This survey consists of 36 questions which evalu-
ate eight dimensions of health: physical functioning, role
limitation due to physical problems, role limitation due to
emotional problems, social functioning, mental health,
energy/vitality, pain and general health perception [12]. A
physical component score and a mental component score
can be calculated in order to summarise the health dimen-
sions [14]. There is a further question asking patients
about their change in health (not included for normative
data). The scoring scale is from 0 (worst QOL) to 100
(best QOL) [14]. Other clinical measures were evaluated as
previously described [11]. Assessment of visual function
was carried out using a LogMAR (log of the minimum
angle of resolution) chart to assess visual acuity and au-
mated perimetry (Humphrey 24–2 central threshold) to
measure the visual field mean deviation. Papilloedema was
evaluated using ocular coherence tomography (OCT)
(Stratus OCTTM V4.0.1, Carl Zeiss, Meditec, Welwyn
Garden City, UK), average retinal nerve fibre layer thick-
ness. A daily headache diary, completed in the week prior
to each visit, evaluated headache severity using a visual
analogue pain scale (VAS), headache frequency (days/week)
and use of analgesia (days/week). A headache
questionnaire (Headache Impact test (HIT-6) score range
36–78) was also completed. ICP was measured by lumbar
puncture by the same physician (AJS) at baseline, 3 and 6
months after all listed outcome measures had been
assessed. Measurements were taken with the patient
breathing steadily in the left lateral position, legs extended
greater than 90° at the hip, allowing adequate time to
ensure a stable ICP reading.

Data and statistical analysis
The statistical analyses were performed using the statistical
package SAS version 9.2 (Cary, NC, USA), Stata
version 13 (Statacorp, Texas, USA) and GraphPad Prism
version 5. Missing data were excluded from analyses.

We used two-tailed p values with p < 0.05 considered
statistically significant. We have not adjusted for mul-
tiple testing due to the fact that the SF-36 domains are
not independent of one another, indeed the component
scores are calculated based on the domain scores. This
reduces the probability of us finding a significant domain
by chance. We have, however, additionally stated in the
tables the threshold p values following a Bonferroni cor-
correction to adjust for the multiple tests for the readers
interest. For longitudinal evaluation, the magnitude of
change from baseline to the end of the intervention was
addressed with a measure of effect size. Comparison SF-
36 data was obtained from published normative data in the
United Kingdom (The Oxford Health and Lifestyles
Survey 1991–1992) [15]. The data was matched for gen-
der and we used a linear regression model, adjusting for
age, to compare the normal population data with the
trial data. QOL changes with therapeutic diet were com-
pared at baseline and 3 months; and 3 months and 6
months: these were analysed using paired t-tests. We
related the changes in QOL with clinical measures and
obtained Pearson’s coefficient to ascertain a linear
relationship.

Statement of ethical approval and consent
This study was approved by the Dudley local research
ethics committee [06/Q2702/64] and informed written
consent was given by all participants.

Results
25 women entered the study and 20 completed the study.
Figure 1 details numbers of individuals and reasons for
non-participation at each stage of the study. Our study in-
cluded females only and had an age range of 19–54 years
Baseline characteristics are shown in Table 1.

Quality of life in idiopathic intracranial hypertension
At baseline, mean 36-Item Short Form Survey scores
were significantly lower in IIH patients (n=24) in 9 of
the 10 domains compared to normative data (a gender
and age matched UK population, n=3338) (Figure 2). The IIH SF-36 summary scores were compared. The mean difference of IIH versus a matched age and gender UK population for physical component score was 10.6 (95% CI: 6.7 to 14.5), p < 0.001, but the mean difference for IIH versus a matched age and gender UK population for mental component score was not significant. 4.8 (95% CI: 0.3 to 9.3), p=0.036.

Quality of life changes with therapeutic diet
The mean differences in scores were evaluated from the beginning to the end of each stage. Our previously published data demonstrates that there was no significant improvement over the observation period (stage 1) but following the diet (stage 2) there was significant improvement in weight, BMI, ICP, papilloedema, visual acuity, headache disability (HIT-6) as well as headache severity and frequency (Table 2). Analgesic use also significantly reduced (p=0.007). Weight, BMI, ICP and HIT-6 showed a particularly large magnitude of change, with effect sizes greater than 0.80.

The 36-Item Short Form Health Survey domains did not improve significantly during stage 1 (no intervention), except for pain (mean change 14.4, p=0.025) and energy/vitality (mean change 10.2, p=0.020). Following therapeutic weight loss (stage 2, low energy diet) the mean differences in 36-Item Short Form Health Survey scores during stage 2 improved significantly in 10 of the 11 domains (Additional file 1). The magnitude of change was particularly large (ES ≥ 0.80) for 5 out of the 11 domains: energy/vitality, pain, general health perception, change in health and physical component score.

We found that there were no significant changes in quality of life 3 months after the dietary intervention had finished, suggesting that the improvement in quality of life was sustained in this period. The change in SF-36 domains do not differ between those who use and do not use acetazolamide (Diamox) for any of the domains.

Relationship between quality of life and clinical outcomes
The linear relationship between the changes in clinical outcomes measures and changes 36-Item Short Form Health Survey domains following the dietary intervention, were then assessed. Despite the significant improvement in visual function, reduction in ICP, papilloedema, BMI and reduction in weight during the dietary intervention, none of these measures correlated with the improvement in QOL scores (Additional file 2).

Interestingly the 36-Item Short Form Health Survey correlated strongly with an improvement in headaches outcomes: Headache Impact Test scores (HIT-6) correlated significantly with all domains of the 36-Item Short Form Health Survey (Additional file 3). In particular, the mental health component score, summarising mental health dimensions (r=-0.88, p < 0.001), the social functioning domain (r=-0.81, p < 0.001) and the energy/vitality domain (r=-0.79, p < 0.001). Headache severity correlated significantly with 10 out of 11 domains, particularly role limitation due to emotional problems (r=-0.78, p < 0.001), mental component score role (r=-0.73, p=0.002) and limitation due to physical problems (r=-0.71, p=0.002) (Table 3). Headache frequency correlated with an improvement in Short Form Health Survey scores which was significant for only 5 out of the 11 domains (p < 0.05) and the correlation was weaker than headache disability (HIT-6) and headache severity (Table 3).

Discussion
This study shows that IIH compromises quality of life which significantly recovers after a therapeutic diet. Improving QOL in IIH is associated with resolving headache but there’s no evidence that it is associated with improvement in other clinical measures (vision, intracranial pressure and BMI). Patients and physicians may undervalue or may not be aware of the broad impact of IIH on health related quality of life. This study expands our knowledge of the quantitative adverse effects on patients and determines what factors can improve QOL.
Table 2 Clinical Outcomes and Quality of Life means (SD) at 0 months (baseline), 3 months and 6 months in Idiopathic intracranial hypertension

<table>
<thead>
<tr>
<th>Clinical outcomes</th>
<th>0 months (baseline)</th>
<th>3 months (baseline)</th>
<th>6 months (baseline)</th>
<th>P-value</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (kg)</td>
<td>101.5 (16.0)</td>
<td>102.5 (16.8)</td>
<td>86.8 (15.6)</td>
<td>&lt;0.001</td>
<td>0.92</td>
</tr>
<tr>
<td>BMI</td>
<td>38.2 (5.0)</td>
<td>38.6 (5.3)</td>
<td>32.6 (4.7)</td>
<td>&lt;0.001</td>
<td>1.12</td>
</tr>
<tr>
<td>Intracranial pressure (cm H2O)</td>
<td>39.8 (5.1)</td>
<td>38.0 (5.0)</td>
<td>30.0 (4.9)</td>
<td>&lt;0.001</td>
<td>1.92</td>
</tr>
<tr>
<td>Headache disability (HIT-6)</td>
<td>57.5 (9.0)</td>
<td>54.5 (1.0)</td>
<td>46.9 (10.1)</td>
<td>0.004</td>
<td>1.18</td>
</tr>
<tr>
<td>Headache severity (VAS)</td>
<td>3.8 (2.4)</td>
<td>4.2 (2.8)</td>
<td>1.9 (2.8)</td>
<td>0.015</td>
<td>0.79</td>
</tr>
<tr>
<td>Headache frequency (days/week)</td>
<td>3.8 (2.9)</td>
<td>4.4 (2.9)</td>
<td>2.1 (2.8)</td>
<td>0.011</td>
<td>0.59</td>
</tr>
<tr>
<td>Papilloedema (OCT)</td>
<td>144.1 (45.5)</td>
<td>135.0 (48.0)</td>
<td>109.3 (27.9)</td>
<td>0.001</td>
<td>0.76</td>
</tr>
<tr>
<td>Visual acuity (LogMar)</td>
<td>-0.02 (0.10)</td>
<td>0.01 (0.11)</td>
<td>-0.06 (0.09)</td>
<td>&lt;0.001</td>
<td>0.40</td>
</tr>
<tr>
<td>Analgesic use (days/week)</td>
<td>2.2 (2.7)</td>
<td>2.2 (2.5)</td>
<td>0.2 (0.4)</td>
<td>0.007</td>
<td>0.74</td>
</tr>
</tbody>
</table>

Quality of life (SF-36)

| Physical functioning                                  | 77.3 (22.9)         | 79.8 (21.2)         | 87.6 (19.4)         | <0.001  | -0.45       |
| Role limitation due to physical problems              | 70.6 (29.3)         | 78.1 (24.7)         | 91.4 (16.9)         | <0.001  | -0.71       |
| Role limitation due to emotional problems             | 78.8 (30.0)         | 76.0 (28.8)         | 90.1 (18.7)         | 0.018   | -0.38       |
| Social functioning                                    | 66.7 (30.3)         | 78.1 (19.6)         | 86.9 (22.8)         | 0.081   | -0.67       |
| Mental health                                         | 63.2 (22.4)         | 67.2 (20.5)         | 74.6 (21.3)         | 0.048   | -0.51       |
| Energy/Vitality                                       | 39.4 (20.8)         | 49.6 (14.4)         | 71.0 (23.4)         | <0.001  | -1.52       |
| Pain                                                  | 53.2 (20.2)         | 67.6 (26.8)         | 85.2 (16.2)         | 0.001   | -1.58       |
| General health perception                             | 53.1 (18.8)         | 53.7 (18.6)         | 72.1 (12.7)         | 0.001   | -1.01       |
| Change in health                                      | 52.1 (19.4)         | 60.4 (19.4)         | 88.1 (17.0)         | <0.001  | -1.86       |
| Physical component score                              | 40.4 (10.3)         | 44.1 (10.5)         | 50.7 (7.4)          | <0.001  | -1.00       |
| Mental component score                                | 45.2 (12.7)         | 47.1 (9.8)          | 52.1 (10.4)         | 0.020   | -0.54       |
| Number                                                | 24                  | 24                  | 20                  |         |             |

HIT-6, Six-item Headache Impact Test; OCT, Optical Coherence Tomography; VAS, Visual Analogue Score; LogMar, Logarithm of the Minimum Angle of Resolution.
The quality of life scale ranges from 0 (worst quality of life) to 100 (best quality of life). There were no significant differences between 0 and 3 months (no diet), except for pain (p=0.025) and energy/vitality (p=0.020). P values in the table indicate changes from 3 to 6 months (following diet). If a Bonferroni correction were applied the p value is reduced to p < 0.0026, but this might represent an overcorrection. Effect size (ES) in the final column indicates the magnitude of change: ES=0.30 indicates mild/low change, ES=0.50 indicates moderate change and ES ≥ 0.80 indicates large change.
in this disease. This study is in keeping with the current literature [8-10] that compared to the normal population QOL, as measured by the 36-Item Short Form Health Survey, QOL in IIH is reduced. This was most notable in the domains energy/vitality, pain and general health perception, p < 0.001.

There are characteristics, such as age, gender and obesity, which could potentially contribute to a lower QOL in IIH, a disease that mainly affects overweight women of child bearing age. For example females report poorer health, except in general health perception, p < 0.001 in UK normative data; there are age differences across the domain score in UK normative data, such as physical functioning being as high as 90.1 (16.4) in women aged 18–24, n=780 and as low as 84.8 (18.3), n=917 in women aged 45–54 [15]. Obesity is associated with a decrease in physical QOL in a dose–response relationship, while morbid obesity (Body Mass Index >40 kg/m²) has been shown to have significantly decreased mental QOL when assessed with 36-Item Short Form Health Survey compared to normal population results [9]. Surprisingly, our results demonstrate that significant weight loss was not associated with improved QOL. The lack of association between obesity and QOL in IIH has been demonstrated in a study which compared IIH to a healthy age-and weight- controls and found lower scores, suggesting that obesity alone cannot explain the lower QOL in IIH [8].

In this interventional study the measurable clinical parameters of vision, perimetry, papilloedema and intracranial pressure significantly improved; yet not one of these variables were significantly associated with enhanced QOL. We have, however, demonstrated a markedly significant relationship between positive QOL score and resolving headache. Our findings agree with earlier literature showing that headache severity correlates with quality of life, rather than headache frequency [16]. This potentially suggests that treatments to modifying headache severity are more important than altering headache frequency when treating IIH patients to improve QOL.

If a Bonferroni correction were applied to account for the multiple domains of the SF-36, the p value is reduced to p < 0.0045, but this might represent an over correction.

Table 3 Correlation between changes in the 36-item short form health survey domains and changes in headache disability, severity and frequency following the therapeutic diet

<table>
<thead>
<tr>
<th>Domain</th>
<th>Headache disability (Headache impact test-6 score)</th>
<th>Headache severity (Visual analogue pain scale)</th>
<th>Headache frequency (days/week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical functioning</td>
<td>-0.67</td>
<td>-0.74</td>
<td>-0.48</td>
</tr>
<tr>
<td></td>
<td>p=0.001</td>
<td>p=0.001</td>
<td>p=0.052</td>
</tr>
<tr>
<td>Role limitation due to physical problems</td>
<td>-0.70</td>
<td>-0.71</td>
<td>-0.53</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001</td>
<td>p=0.002</td>
<td>p=0.029</td>
</tr>
<tr>
<td>Role limitation due to emotional problems</td>
<td>-0.71</td>
<td>-0.78</td>
<td>-0.38</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001</td>
<td>p &lt; 0.001</td>
<td>p=0.14</td>
</tr>
<tr>
<td>Social functioning</td>
<td>-0.81</td>
<td>-0.62</td>
<td>-0.60</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001</td>
<td>p=0.014</td>
<td>p=0.015</td>
</tr>
<tr>
<td>Mental health</td>
<td>-0.64</td>
<td>-0.65</td>
<td>-0.46</td>
</tr>
<tr>
<td></td>
<td>p=0.003</td>
<td>p=0.009</td>
<td>p=0.075</td>
</tr>
<tr>
<td>Energy/Vitality</td>
<td>-0.79</td>
<td>-0.70</td>
<td>-0.42</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001</td>
<td>p=0.004</td>
<td>p=0.11</td>
</tr>
<tr>
<td>Pain</td>
<td>-0.66</td>
<td>-0.59</td>
<td>-0.60</td>
</tr>
<tr>
<td></td>
<td>p=0.002</td>
<td>p=0.018</td>
<td>p=0.010</td>
</tr>
<tr>
<td>General health perception</td>
<td>-0.67</td>
<td>-0.68</td>
<td>-0.49</td>
</tr>
<tr>
<td></td>
<td>p=0.002</td>
<td>p=0.006</td>
<td>p=0.056</td>
</tr>
<tr>
<td>Change in health</td>
<td>-0.58</td>
<td>-0.39</td>
<td>-0.63</td>
</tr>
<tr>
<td></td>
<td>p=0.007</td>
<td>p=0.13</td>
<td>p=0.007</td>
</tr>
<tr>
<td>Physical component score</td>
<td>-0.59</td>
<td>-0.57</td>
<td>-0.55</td>
</tr>
<tr>
<td></td>
<td>p=0.007</td>
<td>p=0.027</td>
<td>p=0.027</td>
</tr>
<tr>
<td>Mental component score</td>
<td>-0.88</td>
<td>-0.73</td>
<td>-0.45</td>
</tr>
<tr>
<td></td>
<td>p &lt; 0.001</td>
<td>p=0.002</td>
<td>p=0.082</td>
</tr>
</tbody>
</table>

If a Bonferroni correction were applied to account for the multiple domains of the SF-36, the p value is reduced to p < 0.0045, but this might represent an over correction.
yet our data suggests that in IIH it is headache severity which most affects quality of life. Of note, headache severity may be more important that headache frequency in determining physical function, role limitation due to emotional problems, mental health, energy and vitality and general health perception and mental component score. Unsurprisingly, a reduction in analgesia use (days/week) correlated with an improvement in quality of life, particularly the pain domain. We evaluated, acetazolamide use, and found there to be no significant difference in QOL for those taking and not taking acetazolamide.

Health-related QOL outcomes are important in deciding whether an intervention is worth adopting [17,18]. A therapeutic weight loss intervention has already been shown to reduce intracranial hypertension, improve headaches, visual function and reduce papilloedema IIH [11].

Our study demonstrates that health-related QOL significantly improves following a therapeutic diet, supporting its use as a suitable treatment for IIH.

There are a number of limitations to this study. Participant numbers included in this study were small, with 25 patients included at baseline and 20 patients completing all stages. This reduces our power to detect differences if they truly exist. We also accept that multiple comparisons were made due to the multiple components of the SF-36 score and clinical measures and accept that 5% of the results could have occurred by chance due to type 1 error. However, the vast majority of the correlations indicated a significant result with r values substantially different from zero which supports the results. Ideally, further studies are required looking at QOL longitudinally with weight loss interventions. Over the initial control stage, there was little significant change in the 36-Item Short Form Health Survey scores, except for energy/vitality and pain. These changes may reflect the positive psychological effect of entering into a research study [19]. Furthermore, some QOL domain measures may require extended periods of time before significant changes are observed. As this study was relatively short these potential differences may have been overlooked. Mental health, in particular, may require a longer period of observation to detect improvements compared to quicker resolving factors such as pain. AJS is currently developing the first national IIIH database in the United Kingdom to enable longitudinal analysis. We did not evaluate co-morbid depression in our cohort but this would certainly be of interest in future studies.

Modern studies are now reporting a lower incidence of blindness in IIH (1–3%), compared to previous studies 6–25% [1,6]. This may be due to increased recognition of the potentially blinding consequences of IIIH in additional to improved management and monitoring of visual symptoms [1,6]. This is the first study to report the relationship between QOL and clinical outcomes.

Conclusions
We have established that QOL significantly recovers after a therapeutic diet. Finally we have shown that improving QOL in IIH is associated with resolving headache and not with other clinical measures (vision, intracranial pressure and BMI). The management of IIH has typically focused on the visual parameters because of the risk of blindness, whilst active treatment of headache is frequently neglected [1,6]. This study highlights the importance of headache in determining QOL in IIH. We therefore recommend that specific headache treatment is key to improving QOL in IIH.

Additional files
Additional file 1: Displays the mean changes in Short-Form Survey score over the observation period (stage 1) and therapeutic diet (stage 2).
Additional file 2: Details the correlation between 36-Item Short Form Health Survey domains and clinical outcomes (visual function, ICP, papilloedema, BMI and weight).
Additional file 3: Displays the correlation between changes in HIT-6 score (x axis) and change in individual 36-Item Short Form Health Survey domains (y axis) during therapeutic diet (stage 2).

Abbreviations
IIH: Idiopathic intracranial hypertension; QOL: Quality of life; SF-36: 36-item short form health survey; BMI: Body mass index; ICP: Intracranial pressure; HIT-6: Six-item headache impact test; LogMAR: Log of the minimum angle of resolution; OCT: Ocular coherence tomography; VAS: Visual analogue pain scale.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AJS conceived and designed the study and collected the clinical data. YM collated the questionnaire data, produced all the figures and tables and wrote the first draft of the manuscript. BLW and SP were responsible for the statistical analysis. SPM critically reviewed the manuscript which all authors reviewed and approved for submission. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank all study participants, study collaborators and Professor Crispin Jenkinson (Nuffield Department of Population Health, University of Oxford) who provided the UK normative data.

Permissions
This manuscript version that is available in public domain license free from RAND Corporation (Research and Development).

Funding
This work was supported by Medical Research Council [G0601430]. Alexandra J Sinclair is funded by an NIHR Clinician Scientist Fellowship (NIHR-CS-011-028).

Author details
1Neurosciences, School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Birmingham B15 2TT, UK. 2Birmingham Clinical Trials Unit (BCTU), School of Health and Population Sciences, University of Birmingham, Birmingham, UK. 3Birmingham Neuro-Ophthalmology Unit, Ophthalmology Department, University Hospitals Birmingham NHS Trust, Queen Elizabeth Hospital Birmingham, Birmingham, UK.

Additional files
Additional file 1: Displays the mean changes in Short-Form Survey score over the observation period (stage 1) and therapeutic diet (stage 2).
Additional file 2: Details the correlation between 36-Item Short Form Health Survey domains and clinical outcomes (visual function, ICP, papilloedema, BMI and weight).
Additional file 3: Displays the correlation between changes in HIT-6 score (x axis) and change in individual 36-Item Short Form Health Survey domains (y axis) during therapeutic diet (stage 2).
References


